Lupus Nephritis Clinical Trial
Official title:
Measurement of Renal Artery Resistive Index as a Predictor of Severity of Lupus Nephritis and Its Response to Treatment
All patients with SLE that will be admitted in internal medicine department from August 2019
to January 2021 are eligible to be targeted and included in the study. The diagnosis of SLE
will be according to the 1997 American college of Romatology revised criteria (Hochberg
1997). SLE patients with lupus nephritis will take kidney biopsy for standard care of
management according to American college of Romatology guidelines 2012. The study will
include three groups as follow:
1 - SLE patients with lupus nephritis. 2- SLE patients without lupus nephritis 3-A group of
age and sex matched healthy individuals. The first group will represent the study group while
the second and third groups group will be taken as control group Exclusion criteria: patients
with
1- Chronic renal failure 2- Diabetes mellitus (DM) 3-Obstructive nephropathy 4- Renal artery
stenosis 5- Hypertension 6- Heart failure 7- Hepatic diseases. 8- Existing intra renal A-V
fistula. 9-Renal vein thrombosis
Aims of the Research :
1. Assessment of the renal resistive index in patients with lupus nephritis (LN), in SLE
patients without lupus nephritis and in the healthy controls.
2. Comparing the renal resistive index values in SLE patients with lupus nephritis with the
SLE patients without LN and healthy controls.
3. Assessment of the correlation between renal resistive index (RRI) and histological
findings in renal biopsy in patients with lupus nephritis.
4. Assessment of the correlation between renal resistive index (RRI) and renal function
parameters (BUN, S Cr and eGFR).
5. Evaluation of the role of RRI as predictor of treatment outcomes in patients with lupus
nephritis.
The study will be enrolled in three steps:
The first step:comparison of renal artery resistive index(RRI) values between study group and
controls.
The second step :correlation between RRI of the patients with lupus nephritis and
histological findings in renal biopsy and/ or kidney function parameters (BUN ,SCr , eGFR).
The third step:the patients with lupus nephritis will be followed up for six month receiving
the usual treatment according to KDIGO guidelines 2012 to demonstrate the response to
treatment in patient with pathological RRI compared to with normal RRI
Status | Not yet recruiting |
Enrollment | 120 |
Est. completion date | January 2022 |
Est. primary completion date | July 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. All patients with lupus nephritis that will be admitted in internal medicine department from August 2019 to January 2021 . 2. All patients with systemic lupus erythematosus(SLE) without renal affection, that will be admitted in internal medicine department from August 2019 to January 2021 . 3. A group of age and sex matched healthy individuals. The first group is the study group while the second and third groups group will be taken as control group Exclusion Criteria: 1. chronic renal failure 2. Diabetes mellitus 3. Obstructive nephropathy 4. Renal artery stenosis 5. Hypertension 6. Heart failure 7. Hepatic diseases. 8. Existing intra renal A-V fistula. 9. Renal vein thrombosis. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Boddi M, Natucci F, Ciani E. The internist and the renal resistive index: truths and doubts. Intern Emerg Med. 2015 Dec;10(8):893-905. doi: 10.1007/s11739-015-1289-2. Epub 2015 Sep 4. Review. — View Citation
Chen Q, He F, Feng X, Luo Z, Zhang J, Zhang L, Wang Y, Tong J. Correlation of Doppler parameters with renal pathology: A study of 992 patients. Exp Ther Med. 2014 Feb;7(2):439-442. Epub 2013 Dec 10. — View Citation
Corapi KM, Dooley MA, Pendergraft WF 3rd. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res Ther. 2015 Apr 28;17:110. doi: 10.1186/s13075-015-0621-6. Review. — View Citation
Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi SI, Gogia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM; American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012 Jun;64(6):797-808. doi: 10.1002/acr.21664. — View Citation
Krumme B. Renal Doppler sonography--update in clinical nephrology. Nephron Clin Pract. 2006;103(2):c24-8. Epub 2006 Mar 10. Review. — View Citation
Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017 Nov 1;56(11):1945-1961. doi: 10.1093/rheumatology/kex260. Review. — View Citation
Sugiura T, Nakamori A, Wada A, Fukuhara Y. Evaluation of tubulointerstitial injury by Doppler ultrasonography in glomerular diseases. Clin Nephrol. 2004 Feb;61(2):119-26. — View Citation
Tao JL, Li H, Li C, Xu XW, Li JF, Yi N, Liu DY, Qin Y, Cai JF, Liu BY, Xu H, Gao RT, Ye WL, Ye W, Li XM, Li XW. [Risk factors of post-renal biopsy bleeding]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2008 Jun;30(3):313-7. Chinese. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The mean of renal artery resistive(RRI) in each group | the sum of RRI values in each group divided by the number of individuals in each group | 30 minutes | |
Primary | Correlation between Renal Resistive Index and chronicity index in renal biopsy of patients with Lupus Nephritis | Renal Resistive Index will be measured as :RRI = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity .chronicity index score in renal biopsy will be calculated according to the Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis 2017. Result of renal biopsy will be reported within one weak.Correlation between RRI and chronicity index using correlation tests using SPSS version 20; pearson correlation test if the data are normally distributed and spearman correlation test if the data aren't normally distributed | one weak | |
Secondary | The mean of renal artery resistive index in each histological class in renal biopsy | pathological RRI(RRI>0.7) .Renal biopsy will be evaluated according to the Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis 2017. There are 6 classes of lupus nephritis in renal biopsy. Number of patients in each class will be identified. the sum of RRI values in each class divided by the number of patients in each class | one weak | |
Secondary | Correlation between renal artery resistive index (RRI) and renal function parameters (BUN, SCr and eGFR) in patients with lupus nephritis | measurement of RRI in each patient with lupus nephritis . Blood sample from the same patient to measure blood urea nitrogen (BUN), serum creatinine(S Cr) and estimated glomerular filtration rate (eGFR) (using CKD-EPI Equation) | two hours | |
Secondary | Correlation between renal artery resistive index and response to treatment in patients with lupus nephritis | RRI will be measured for every patient with lupus nephritis at the beginning of the study. the patients will be followed for 6 months .BUN,S Cr , eGFR and and 24 h urinary protein excretion will be measured at the beginning of the study and every month for sex months to determine degree of response to treatment in patients with pathological RRI(0.7) compared to those with normal RRI. | 6months | |
Secondary | Correlation between RRI and mean of hemoglobin level in patients with lupus nephritis. | RRI will be measured for every patient of lupus nephritis at the beginning of the study.Hemoglobin level will be measured at the beginning of the study and every month for sex months and the mean will be calculated | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02936375 -
The Iguratimod Effect on Lupus Nephritis (IGeLU)
|
Phase 2 | |
Completed |
NCT03597464 -
Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin
|
Phase 3 | |
Recruiting |
NCT01226147 -
Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis
|
Phase 2 | |
Completed |
NCT01206569 -
Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis
|
Phase 4 | |
Active, not recruiting |
NCT00569101 -
A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis
|
Phase 2 | |
Terminated |
NCT00368264 -
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
|
Phase 2/Phase 3 | |
Completed |
NCT00371319 -
Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis
|
Phase 4 | |
Completed |
NCT00298506 -
Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)
|
N/A | |
Completed |
NCT00094380 -
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
|
Phase 1/Phase 2 | |
Terminated |
NCT04376827 -
A Study of Guselkumab in Participants With Active Lupus Nephritis
|
Phase 2 | |
Completed |
NCT03610516 -
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.
|
Phase 2 | |
Recruiting |
NCT03526042 -
Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis
|
N/A | |
Withdrawn |
NCT03859570 -
Pentoxifylline in Lupus Nephritis
|
Phase 4 | |
Completed |
NCT03664908 -
Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)?
|
N/A | |
Completed |
NCT01085097 -
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
|
Phase 2 | |
Active, not recruiting |
NCT05704088 -
SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients
|
Phase 4 | |
Not yet recruiting |
NCT06429800 -
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis
|
Phase 1 | |
Recruiting |
NCT02226341 -
ACTHar in the Treatment of Lupus Nephritis
|
Phase 4 | |
Recruiting |
NCT02453997 -
Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis
|
N/A | |
Completed |
NCT01470183 -
Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients
|
N/A |